FY2025 EPS Estimates for REGN Boosted by Cantor Fitzgerald

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Investment analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for Regeneron Pharmaceuticals in a research note issued to investors on Wednesday, October 29th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will earn $35.11 per share for the year, up from their prior estimate of $31.81. Cantor Fitzgerald has a “Overweight” rating and a $740.00 price target on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share. Cantor Fitzgerald also issued estimates for Regeneron Pharmaceuticals’ FY2026 earnings at $36.70 EPS.

A number of other brokerages have also commented on REGN. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research report on Wednesday. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Sanford C. Bernstein increased their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Royal Bank Of Canada increased their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday. Finally, Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $802.36.

Regeneron Pharmaceuticals Stock Down 0.3%

REGN stock opened at $651.80 on Friday. The company has a 50-day moving average of $581.80 and a two-hundred day moving average of $565.22. The stock has a market capitalization of $69.08 billion, a price-to-earnings ratio of 15.61, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $883.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the prior year, the company earned $12.46 earnings per share. The business’s quarterly revenue was up .9% compared to the same quarter last year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 7.02% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares during the last quarter. Mather Group LLC. increased its stake in Regeneron Pharmaceuticals by 20.2% in the 1st quarter. Mather Group LLC. now owns 1,090 shares of the biopharmaceutical company’s stock valued at $691,000 after buying an additional 183 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Regeneron Pharmaceuticals by 13.6% in the 1st quarter. Vontobel Holding Ltd. now owns 7,339 shares of the biopharmaceutical company’s stock valued at $4,655,000 after buying an additional 881 shares during the last quarter. Cidel Asset Management Inc. increased its stake in Regeneron Pharmaceuticals by 15.7% in the 1st quarter. Cidel Asset Management Inc. now owns 383 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 52 shares during the last quarter. Finally, DAVENPORT & Co LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $271,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.